Müller, Anne http://orcid.org/0000-0002-2456-2492
Hebben, Fabian http://orcid.org/0009-0003-6401-3433
Dillen, Kim
Dunkl, Veronika
Goereci, Yasemin
Voltz, Raymond
Löcherbach, Peter
Warnke, Clemens http://orcid.org/0000-0002-3510-9255
Golla, Heidrun http://orcid.org/0000-0002-4403-630X
Müller, Dirk
Hobus, Dorthe
Bonmann, Eckhard
Schwartzkopff, Franziska
Nelles, Gereon
Palmbach, Gundula
Temmes, Herbert
Franke, Isabel
Haas, Judith
Strupp, Julia
Gerbershagen, Kathrin
Becker-Peters, Laura
Burghaus, Lothar
Hellmich, Martin
Paus, Martin
Ungeheuer, Solveig
Kochs, Sophia
Stock, Stephanie
Joist, Thomas
Limmroth, Volker
,
Funding for this research was provided by:
Innovation Funds of the Federal Joint Committee (01VSF19029, 01VSF19029, 01VSF19029, 01VSF19029, 01VSF19029, 01VSF19029, 01VSF19029, 01VSF19029)
Universitätsklinikum Köln
Article History
Received: 23 November 2023
Accepted: 11 March 2024
First Online: 10 April 2024
Declarations
:
: Participants were provided with oral and written information about the trial and provided written informed consent. Ethical approval was obtained from the Ethics Committee of the University of Cologne (#20–1436). The trial is registered in the German Register for Clinical Studies (DRKS) (DRKS00022771) and is conducted under the Declaration of Helsinki.
: Not applicable.
: Clemens Warnke has received institutional support from Novartis, Alexion, Sanofi Genzyme, Janssen, Biogen, Merck and Roche. The other authors declare that they have no competing interests.